Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis

Mäkäräinen L, Leo Mäkäräinen, L Mäkäräinen, Rönnberg L, Lars Rönnberg, L Rönnberg, A Kauppila, Antti Kauppila, Kauppila A
Fertility and sterility · 1996 · vol. 65(1) , pp. 29–34 · doi:10.1016/s0015-0282(16)58023-6 · PMID:8557151 · W35401484
RCT OA: closed CC0 ⤵ 35 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-10 ⓘ

Medroxyprogesterone acetate supplementation reduced hot flashes and bone calcium loss when co-administered with a GnRH agonist for endometriosis treatment, without affecting the drug's efficacy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To examine the effects of concomitant use of goserelin and medroxyprogesterone acetate (MPA) in the treatment of endometriosis. DESIGN: Thirty-eight women with laparoscopically confirmed endometriosis were treated with once-a-month s.c. injections of goserelin acetate 3.6 mg (Zoladex depot; Zeneca Pharmaceutics, Cheshire, United Kingdom) randomly combined with either MPA (100 mg daily; n = 19) or a placebo (one tablet daily; n = 19) in a double-blind trial. Symptoms and side effects were monitored for a treatment period of 6 months and a follow-up period of 6 months. Blood and urine samples were collected for the assessment of endocrine and biochemical parameters. A second-look laparoscopy was performed 6 months after the treatment in 29 women. RESULTS: The extent of endometriosis was diminished similarly in both treatment groups, as were pelvic symptoms. Fewer women in the MPA group had hot flushes and sweating at 3 and 6 months of treatment. Sex hormone-binding globulin decreased in the MPA group but not in the placebo group. Consequently, the E2 index (E2/SHBG X 100), reflecting the free fraction of E2, fell more in the placebo group than it did in the MPA group. The increased urinary excretion of calcium observed during placebo treatment was prevented by MPA. CONCLUSION: High-dose MPA combined with a GnRH agonist (GnRH-A) diminished some antiestrogenic effects of the agonist. A reduction in hypoestrogenic side effects and a possible bone-sparing effect can be regarded as beneficial, especially as the good effect of the GnRH-a on endometriotic implants and pelvic symptoms prevailed.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Estrogen Antagonists Goserelin Medroxyprogesterone Acetate Adult Adult Double-Blind Method Double-Blind Method Drug Therapy, Combination Drug Therapy, Combination Endometriosis Endometriosis Estrogen Antagonists Estrogen Antagonists Female Female Goserelin Goserelin Goserelin Humans

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (31)

Cited by (35)

Source provenance

europepmc
last seen: 2026-10-14T06:08:39.101224+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:59:43.143194+00:00
License: CC0 · commercial use OK